Abstract
Although the precise etiology of inflammatory bowel diseases (IBD) still remains unclear, considerable progress has been made in the identification of novel signal transduction pathways that elucidate the immunopathogenesis involved in the perpetuation of the inflammatory process. As both ulcerative colitis and Crohns disease are associated with an increased risk for developing colorectal cancer (CRC) and precancerous dysplastic epithelial changes, further studies have concentrated on finding a common signaling pathway that could serve as a mechanistic link between inflammation and associated colonic cancer in IBD. This review presents the current data concerning the pathogenic role of the IL-6/STAT-3 trans signaling pathway in IBD and colorectal cancer. Furthermore it evaluates the possible therapeutic potential of targeting this pathway for the therapy of IBD and CRC.
Keywords: IBD, colon cancer, IL-6, trans signaling, STAT-3, Bcl-xl
Current Drug Targets
Title: Signaling Molecules: The Pathogenic Role of the IL-6/STAT-3 Trans Signaling Pathway in Intestinal Inflammation and in Colonic Cancer
Volume: 9 Issue: 5
Author(s): R. Atreya and M. F. Neurath
Affiliation:
Keywords: IBD, colon cancer, IL-6, trans signaling, STAT-3, Bcl-xl
Abstract: Although the precise etiology of inflammatory bowel diseases (IBD) still remains unclear, considerable progress has been made in the identification of novel signal transduction pathways that elucidate the immunopathogenesis involved in the perpetuation of the inflammatory process. As both ulcerative colitis and Crohns disease are associated with an increased risk for developing colorectal cancer (CRC) and precancerous dysplastic epithelial changes, further studies have concentrated on finding a common signaling pathway that could serve as a mechanistic link between inflammation and associated colonic cancer in IBD. This review presents the current data concerning the pathogenic role of the IL-6/STAT-3 trans signaling pathway in IBD and colorectal cancer. Furthermore it evaluates the possible therapeutic potential of targeting this pathway for the therapy of IBD and CRC.
Export Options
About this article
Cite this article as:
Atreya R. and Neurath F. M., Signaling Molecules: The Pathogenic Role of the IL-6/STAT-3 Trans Signaling Pathway in Intestinal Inflammation and in Colonic Cancer, Current Drug Targets 2008; 9 (5) . https://dx.doi.org/10.2174/138945008784221116
DOI https://dx.doi.org/10.2174/138945008784221116 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evaluation of microRNA Stability in Plasma and Serum from Healthy Dogs
MicroRNA Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities
Current Pharmaceutical Design Nuclear Hormone Receptors and Female Reproduction
Current Molecular Medicine Pharmacogenetics of the Cytochromes P450
Current Topics in Medicinal Chemistry Update of QSAR & Docking Studies of the GSK-3 Inhibitors
Current Bioinformatics Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism Combination of Phytochemicals as Adjuvants for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Improvement of Adoptive Cellular Immunotherapy of Human Cancer Using Ex-Vivo Gene Transfer
Current Gene Therapy Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Epigenetic Aberrations and Targeted Epigenetic Therapy of Esophageal Cancer
Current Cancer Drug Targets uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy
Current Drug Targets Role of Netrin-1 Beyond the Brain: From Biomarker of Tissue Injury to Therapy for Inflammatory Diseases
Recent Patents on Biomarkers EDITORIAL (Thematic Issue: Special Thematic Issuue: Development of Biomarkers in Tumors of Digestive System Part I)
Anti-Cancer Agents in Medicinal Chemistry MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Notch Signalling Pathways and Their Importance in the Treatment of Cancers
Current Drug Targets Recent Approaches to Improve the Antitumor Efficacy of Temozolomide
Current Medicinal Chemistry Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry